May 21, 2008, A U.K. appellate court has reversed a lower court order revoking Merck & Co. Inc.'s patent for male pattern baldness treatment Propecia, finding that Actavis UK Ltd.'s challenge was an “unusual case” in which a change of dosage for a drug was patentable. The court has cited European patent law precedents for this decision.
The Judgement can be read here.
No comments:
Post a Comment